Preview

Медицинский Совет

Расширенный поиск

Острая респираторная инфекция: отделяя зерна от плевел

https://doi.org/10.21518/2079-701X-2019-11-166-170

Полный текст:

Аннотация

В рамках XXI Конгресса педиатров России с международным участием «Актуальные проблемы педиатрии», проходившего в начале 2019 года, состоялся междисциплинарный симпозиум по современным принципам лечения детей с острыми респираторными заболеваниями. В своих докладах зарубежные и отечественные эксперты осветили самые обсуждаемые темы педиатрии: выбор и применение иммуностимулирующей терапии при ведении детей с рецидивирующими инфекциями, тактику лечения кашля у детей, влияние антибиотикотерапии на микробиом и рациональные подходы к антибактериальной терапии в детском возрасте. 

Об авторе

Статья Редакционная

Россия


Список литературы

1. Feleszko W., Ruszczynski M., Zalewski B.M. Nonspecific immune stimulation in respiratory tract infections. Separating the wheat from the chaff. Paediatric Respiratory Reviews. 2014;15(2):200-2006.

2. Del-Rio-Navarro B.E. et al. Immunostimulants for preventing respiratory tract infection in children. The Cochrane Library. 2011;6.

3. Yin J. et al. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. International Immuno pharmaco logy. 2018;54:198–209.

4. Esposito S. et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Current opinion in allergy and clinical immunology. 2018;18(3):198.

5. Chatterjee S. et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5® and Bifidobacterium BB-12® for prevention of antibioticassociated diarrhoea. JAPI. 2013;61:708-712.

6. Roth M., Pasquali C., Stolz D., Tamm M. Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelialcells via Erk1/2 mitogen activated protein kinase and cAMP. PLoS ONE. 2017;12(11):e0188010.

7. Liu Y.W., Dong S.H., Zhan G.Y., Tan H.Z., Peng Y.Q., Wei F. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis. Eur. Rev. Med. Pharmacol. Sci. 2017;21(14):3332–3336.

8. Berber A.C., Del-Rio-Navarro B.E. Use of BronchoVaxom® in private practice: Phase IV trial in 587 children. Clinical therapeutics. 1996;18(6):1068-1079.

9. Zagar S., Lofler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec. 1988;50(6):397-404.

10. Gomez Barreto D. et al., Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children. Allergol Immunopathol (Madr). 1998 Jan-Feb;26(1):17-22.

11. Geiler J., Michaelis M., Naczk P., Leutz A., Langer K., Doerr H.W., Cinatl J. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of proinflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010;79:413-420. doi:10.1016/j.bcp.2009.08.025.

12. Mata M. et al. N-acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011 Sep. 1;82(5):548-555.

13. Chalumeau M., Duijvestijn Y.C.M. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients withoute chronic broncho-pulmonary disease (Review). The Cochrane Library. 2013;lssue 5.

14. Ardatskaya M.D., Belmer S.V. and coauth. Intestinal dysbiosis (dysbacteriosis): modern representation of the problem, complex diagnostics and therapeutic correction. Eksperimental’naya i klinicheskaya gastroenterologiya. 2015;117(5):13-50. (In Russ.)

15. Goldenberg J.Z., Yap C., Lytvyn L., Lo C., Beardsley J., Mertz D., Johnston B.C. The use of probiotics to prevent Clostridium difficile diarrhea associated with antibiotic use. Reviews. 2017;lssue 12.

16. Sheu B.-Sh., Cheng H.-Ch. et al. Pretreatment with Lactobacillusand Bifidobacteriumcontaining yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr. 2006;83:864–9.

17. Chatterjee S. et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5® and Bifidobacterium BB-12® for prevention of antibioticassociated diarrhoea. JAPI. 2013;61:708-712.

18. Инструкция по применению лекарственного препарата Линекс® Форте http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1511cfe01711-463f-8370-e5d25c72c5db&t=


Просмотров: 56


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)